Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India · Delayed Price · Currency is INR 3,347.80
+52.40 (1.59%)
Aug 14, 2025, 3:29 PM IST
Dr. Lal PathLabs Employees
Dr. Lal PathLabs had 4,980 employees as of March 31, 2025. The number of employees increased by 881 or 21.49% compared to the previous year.
Employees
4,980
Change (1Y)
881
Growth (1Y)
21.49%
Revenue / Employee
5.08M INR
Profits / Employee
1.03M INR
Market Cap
279.58B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,980 | 881 | 21.49% |
| Mar 31, 2024 | 4,099 | 51 | 1.26% |
| Mar 31, 2023 | 4,048 | -62 | -1.51% |
| Mar 31, 2022 | 4,110 | 114 | 2.85% |
| Mar 31, 2021 | 3,996 | 73 | 1.86% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Divi's Laboratories | 10,542 |
| Cipla | 30,313 |
| Apollo Hospitals Enterprise | 42,497 |
| Mankind Pharma | 26,978 |
| Zydus Lifesciences | 27,917 |
| Fortis Healthcare | 12,237 |
| Alkem Laboratories | 18,785 |
Dr. Lal PathLabs News
- 7 weeks ago - Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market - Business Upturn
- 7 weeks ago - Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests - Business Upturn
- 4 months ago - Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY - Business Upturn
- 10 months ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
- 10 months ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
- 10 months ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
- 10 months ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
- 10 months ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn